Drug Approval | May 05, 2026
Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Patalganga plant received zero observation from USFDA earlier
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Subscribe To Our Newsletter & Stay Updated
